Clinical Trials on Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant

Total 343 results

Astellas Pharma Inc
Seagen Inc.

Completed

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201)

Urologic Neoplasms | Urinary Bladder Neoplasms | Carcinoma, Transitional Cell | Ureteral Neoplasms | Urothelial Cancer | Urethral Neoplasms | Renal Pelvis Neoplasms

United States, Korea, Republic of, Spain, France, Germany, Italy, Japan, Netherlands
Australian and New Zealand Urogenital and Prostate...

Recruiting

ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) (UNICAB)

Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell Carcinoma

Australia
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Advanced Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Advanced Sarcomatoid Renal Cell Carcinoma

United States
Australian and New Zealand Urogenital and Prostate...
Bristol-Myers Squibb

Active, not recruiting

Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (UNISoN)

Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation Carcinoma

Australia
Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center; University of Chicago

Recruiting

A Genotype-Phenotype Urothelial Cancer Registry

Bladder Cancer | Urothelial Cancer | Ureter Cancer | Renal Pelvis Cancer

United States
National Cancer Institute (NCI)

Withdrawn

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

Urothelial Carcinoma | Renal Pelvis and Ureter Urothelial Carcinoma | Bladder Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage IVA Bladder Cancer AJCC v8 | Bladder Urothelial Carcinoma | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

Canada
UroGen Pharma Ltd.

Withdrawn

Efficacy and Safety of UGN-101 in Recurrent Patients (Retreatment)

Carcinoma | Transitional Cell Carcinoma | Transitional Cell Cancer of the Renal Pelvis and Ureter

Israel, United States
zr Pharma & GmbH
Foundation Medicine

Terminated

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS)

Bladder Cancer | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Muscle Invasive Bladder Cancer | Ureter Carcinoma | Renal Pelvis Carcinoma | Urinary Bladder Carcinoma | Urethra Carcinoma

United States, Spain, France, Italy, Germany, United Kingdom
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PROSPER)

Metastatic Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Unclassified Renal Cell Carcinoma | Stage II Renal Cell Cancer AJCC v7

United States, Canada, Israel
National Cancer Institute (NCI)

Terminated

Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Transitional Cell Carcinoma of the Bladder | Localized Transitional Cell Cancer of the...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Exelixis

Active, not recruiting

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Malignant Neoplasms of Urinary Tract | Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma

United States
Hao Zeng

Not yet recruiting

A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | First-line Treatment | Non Clear Cell Renal Cell Carcinoma

China
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma | Renal Cell Carcinoma With Sarcomatoid Features

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer

Metastatic Renal Cell Cancer | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Kidney Medullary Carcinoma | Kidney Oncocytoma | Carcinoma of the Collecting Ducts of Bellini

United States
UroGen Pharma Ltd.

Completed

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus)

Carcinoma, Transitional Cell | Transitional Cell Carcinoma of Renal Pelvis

United States, Israel
Sumitomo Pharma America, Inc.

Terminated

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Fallopian Tube Cancer | Primary Peritoneal Cancer | Urothelial Carcinoma | Renal Cell Carcinoma (RCC) | Platinum-resistant Ovarian Cancer (PROC) | Serous Epithelial Ovarian Cancer

United States, Canada
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Renal Cell Carcinoma | Cervical Cancer | Endometrial Cancer | Urothelial Carcinoma | Ovarian Cancer Recurrent

China
University of Texas Southwestern Medical Center
National Cancer Institute (NCI); Howard Hughes Medical Institute

Recruiting

An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

Kidney Cancer | Renal Cell Carcinoma | Urothelial Carcinoma | Hereditary Leiomyomatosis and Renal Cell Cancer | Metastatic Urothelial Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | HLRCC | Clear Cell Carcinoma | Metastatic Kidney Cancer | Fumarate Hydratase Deficiency | Succinate...

United States
H. Lee Moffitt Cancer Center and Research Institute

Completed

Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer

Carcinoma, Transitional Cell | Bladder Cancer | Urethra Cancer | Ureter Cancer | Renal Pelvis Cancer

United States
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors

Melanoma | Urothelial Carcinoma | Renal Carcinoma

China
Institut du Cancer de Montpellier - Val d'Aurelle

Active, not recruiting

A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer (GETUGV04)

Infiltrating Bladder Urothelial Carcinoma

France
Mayo Clinic

Recruiting

Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study

Clear Cell Renal Cell Carcinoma | Urothelial Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Kidney Oncocytoma | Clear Cell Papillary Renal Tumor

United States
Weill Medical College of Cornell University

Terminated

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

Metastatic Renal Cell Carcinoma | Metastatic Urothelial Carcinoma

United States
Oslo University Hospital

Completed

Prospective Trial for Examining Hematuria Using Computed Tomography (PROTEHCT)

Renal Cell Carcinoma | Urothelial Carcinoma | Renal Stone | Renal Cyst

Norway
Duke University

Completed

INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers

Metastatic Renal Cell Carcinoma | Metastatic Urothelial Carcinoma | Metastatic Castration-resistant Prostate Cancer (mCRPC)

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional...

Canada
National Cancer Institute (NCI)

Completed

Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter

United States
Dana-Farber Cancer Institute
ImmunityBio, Inc.; Kidney Cancer Association

Not yet recruiting

A Phase 0 Pilot Study of Memory-like Natural Killer (NK) Cell Immune Therapy in Combination With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Renal Cell Carcinoma | Urothelial Carcinoma | Renal Carcinoma

United States
Case Comprehensive Cancer Center

Recruiting

Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer

Renal Cell Cancer | Urothelial Cancer of Renal Pelvis | Cutaneous Malignant Melanoma

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors

Urothelial Carcinoma | Metastatic Castration-resistant Prostate Cancer | Clear Cell Renal Carcinoma

China
University of California, San Francisco
Prostate Cancer Foundation; Strata Oncology

Active, not recruiting

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

Prostate Cancer | Advanced Renal Cell Carcinoma | Genitourinary Cancer | Advanced Urothelial Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Metastatic Clear Cell Renal Cell Carcinoma | Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Urothelial Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Janssen Research & Development, LLC

Active, not recruiting

Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Bladder Urothelial Carcinoma | Metastatic Kidney Carcinoma | Malignant Urinary System Neoplasm

United States
Eli Lilly and Company

Completed

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Carcinoma of Urinary Tract | Urethral Carcinoma | Carcinoma of Ureter | Carcinoma of Renal Pelvis

United States, Canada
Pharmacyclics LLC.

Completed

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Metastatic Renal Cell Carcinoma | Metastatic Colorectal Adenocarcinoma | Advanced Gastric Adenocarcinoma | Advanced Urothelial Carcinoma

United States, Korea, Republic of, Spain, United Kingdom
iOMEDICO AG

Recruiting

Registry Platform Urologic Cancer (CARAT)

Renal Cell Carcinoma | Urothelial Carcinoma

Germany
Sumitomo Pharma America, Inc.

Withdrawn

A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies

Renal Cell Carcinoma | Urothelial Carcinoma | Urologic Malignancies
National Cancer Institute (NCI)

Recruiting

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Lymph Nodes | Metastatic Malignant Neoplasm in the Soft Tissues | Metastatic Malignant Neoplasm in the Viscera and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Completed

Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder

United States
GlaxoSmithKline

Completed

Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)

Epilepsy | Renal Cell Carcinoma | Hypertension | Diabetes | Restless Legs Syndrome | Pancreatic Cancer | Neuropathic Pain | Chronic Pancreatitis | Renal Cancer | Renal Pelvis Cancer
University of Erlangen-Nürnberg Medical School

Recruiting

Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy (ST-ICI02)

Renal Cell Carcinoma | Esophageal Cancer | NSCLC | Urothelial Carcinoma | HNSCC | Squamous Cell Carcinoma of the Skin | Small Cell Bronchial Carcinomas

Germany
Tulane University Health Sciences Center

Completed

Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

HIV Infection | Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Metastatic Lung Non-Small Cell Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Melanoma | Recurrent Head and Neck Carcinoma | Recurrent Renal Cell Carcinoma | Advanced... and other conditions

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional... and other conditions

United States
University of Oklahoma
WindMIL Therapeutics

Terminated

Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma (WindMIL-001)

Renal Cell Carcinoma | Urothelial Carcinoma

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Refractory Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer... and other conditions

United States

Clinical Trials on Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations